Question.4994 - Week 7: Submit Individual Case AnalysisPrepare and submit a 4-5 page case analysis on Theranos in which you discuss whether you, as Tyler Shultz, would have gone to regulators if you were in his position. Why or why not? What is your assessment of the defense strategy that puts blame on the "Silicone Valley startup culture"?
Answer Below:
Case xxxxxxxx Tyler xxxxxx Theranos xxx the xxxxxx of xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx is xxxxx considered xx be xxx of xxx ethical xxxxxxxx most xxxxxxx in xxxxxx corporate xxxxxxx from xxx time xx was xxxx still xxxxxxxxxx health xxxx startup xxx of xx came xxxxxxxx down xx the xxxxxxxxx doors xxxx and xxxx her xxxxxx walked x young xxxxxxxx of xxxxxxxx Tyler xxxxxx whom xxxx would xxxxx know xx the xxxxxxxx of xxxxxx Shultz x member xx the xxxxxxxx board xxxxx discovered xxxxx were xxxx about xxx cutting-edge xxxx blood-testing xxxxxxxxxx they xxxx commercializing xxxxxxx family's xxxxxxx and xxxxxxxxxxxx ambitiousness xxx ethical xxxxxxxxxxxxxx Tyler xxxxxxx to xxxxxx the xxxxxxxxxx The xxxxx would xxxxxxx if x would xx to xxxxxxxxxx in xxx case xx being xx Tyler's xxxxx and xx an xxxxxxxxxxxxx of xxxx the xxxxxxx has xxxx in xxx defense xxxxxxxxxxx its xxxxxxx to xxx Silicon xxxxxx startup xxxxxxx I xxxxx argue xxxxx on xxxxxxxx available xxxxxxx and xxxxxxx frameworks-such xx Rest's xxxxxxxxxxxxxx Model xxx stakeholder xxxxxxx that xxxxxxxxxxxxxxx was xxx only xxxxxxxxx but xxxxxx ethically xxxxxxxxx The xxxxxxx culture xxxxxxx fails xx that xxxxx ambition xxxx not xxxxxx falsehood xxxx it xxxxx to xxxxxxx safety xx risk xxxxx I xxxx Gone xx Regulators xxx or xxx Not xxxxx I xx find xxxxxx in xxxxx Shultz's xxxxx I xxxxx seek xxx appropriate xxxxxxxxxx Given xxx enormous xxxxxxxx he xxxx have xxxx personally xxx professionally x applaud xxx decision xx come xxxxxxx morally xx was xxx right xxxxx to xx According xx Rest's xxxxxxxxxxxxxx Model xxxxxxx action xxxxxxx from xxxxx awareness xx moral xxxxxxxx to xxxxx intent xxxxxxxx by xxxxx action xxxxxxx Brown xxxxx knew xx these xxxxxxxxxx for xx witnessed xxxxxxxxx Theranos xxxxxxxxxx test xxxxxxx and xxxxxxxxx misleading xxxxxxxxxxxx Tyler xxx to xxxx extent xxxxxxxxx by xxxxxxxxxxxx patients xxxxxxx investors xxx the xxxxxxx public xxx groups xx stakeholder x theory xxxxxxx that x business xxxxx to xxxxxxxx the xxxxxxxxx of xxx those xxxxxxxxxxxx just xxxxxxxxxxxx Theranos' xxxxxxxxx was xxxxxxx on xxx customers xxxxx blood xxxxx would xxxxxx the xxxxxxxxxx for xxxxxxx diseases xxxx cancer xxx HIV xxxxxxx that xxx incorrect xxxxx have xxxx harmful xxxxxxxxxxxx The xxxxxxxx Center xxx Applied xxxxxx notes xxxxxx that xxxxx acknowledged xxxx his xxxxxxx would xxxx complicate xxx in xxx harm xxxxx Clara xxxxxxxxxx n x Although xxxxxxx payment xxx high xxxxxxxx family xxxxxxxxx threats xx lawsuits xxx professional xxxxxxxxxxx it xxxxx goes xx show xxxx ethical xxxxxxxxxxxxxxx is xxxxxxxxxx far xxxx convenient xxx other xxxxxxx silence-would xxxx made xxx complicit xx deception xxx harm xxxxxxxxx if x align xxxx core xxxxx values xxx considerations xx public xxxxxx I xxxxx take xxx same xxxxxx of xxxxxx Ethical xxxxxxxxxx and xxxxxxxxxxx DutyThere xxx many xxxxxxx dilemmas xx the xxxxxxxxx environment xxx ethical xxxxxxxxxxxxxxx could xxx some xxxx or xxxxxxxxxx guidance xx this xxxxx the xxxxxxxxx of xxxxxx Four-Component xxxxx cannot xx overemphasized xxx model xxxxxx with xx awareness xx the xxxxx issue-an xxxxx such xx identification xx Tyler xx patients xxxxxxxxx false xxxxxxxx blood xxxx results xxxx is xxxxx judgment x decision xx what xx right xx weighed xxx moral xxxxxxx of xxxxxx and xxxxxxx that xxxxxxxxxx at xxxxxxxx without xxxxxxx concerns xxxxx violate xxx ethical xxxxxxxxx The xxxxx step xx moral xxxxxx giving xxxxxxxx to xxxxx values xxxxx external xxxxxxxx Finally xxxxx action xx taking xxx steps xx correct xxxxxxxxxx which xxxxx did-by xxxxxxxxxx regulators xxx journalists xxxxxxx Brown xxx position xx further xxxxxxxxxx by xxxxxxxxxxx theory xxxxxxxxxx decisions xxxxxxxxx affected xxxx stakeholders xxxxxxxx employees xxxxxxxxx and xxx public xx business xxxxxx leadership xx supposed xx balance xxxxx interests xxxxxxx bias xx was xxxxx meant xx be x secret xxxxxxxx of xxx stakeholders xxxxxxxx favored xxxxxxx and xxxxxxxxx over xxxxxxxxxx its xxxxxxxxxxxx Therefore xxxxxxxxxxxxxx would xxxxx as x last xxxxxx to xxxxxxxxx ethical xxxxxxx here xxxxxxxx of xxx Silicon xxxxxx Startup xxxxxxx DefenseTheranos xxxxxxx even xxxxxxxx themselves xx the xxxxxxx that xxxxx practices xxxx in xxxx with xxxxxxxxx Silicon xxxxxx startup xxxxxxx characterized xx aggressive xxxxxx covering xx of xxxxxxx and xxxxxxx fake xx till xxx make xx But xxxx defense xxxxxx apart xx the xxxxx of xxxxxx health xxx medical xxxxxxx Innovation xxxx not xxxxxx endangering xxxxx Ethics xxxxxxxxx This xx something xx Ethics xxxxxxxxx explains xxxx there xx difference xx iterative xxxxxxxxxx and xxxxxxxx fraud xxxx companies xxxx start xxxxx failing xxxxx but xxxxxxxxxxxx covering xxx defects xx a xxxxxxx that xxxxxxxx has x bearing xx people's xxxxxx is xxxxxxxx the xxxxxxx line xxxxxxx this xxxxxxx undermines xxxxxxxxxxxxxx If xxxxx unethical xxxxxxxx would xxxx an xxxxxxxxxxx in xxxxxxx then xx company xxxxx be xxxxxxxxxxx for xxxxxx Ethics xxxxxxxxx The xxxxxxx Valley xxxxxxx culture xxxxxxx holds xxxxxx to xxx narrative xx innovation xx any xxxxxxxxxxxx that xxxxxxxxxx exaggeration xxxx scaling xxxx little xxxxxxx or xxxxxxxxxxx development xxxxx to xxxxxxxx a xxxxxxxxxxx edge xxx rules xx thumb xxxxx this xxx hold xx a xxxxxxxx company xx tech-gadget xxxxxxxx applying xxx same xxxxxxxxx to xxxxxx care xxxxxxx the xxxxxxx borderline xxxxx Clara xxxxxxxxxx n x Theranos xxxxxxx its xxxxxxxx for xxxxxxxx purposes xxxx though xxx internal xxxxxxxxx would xxxx indicated xx the xxxxxxxxxxxx that xxx tests xxxx not xxxxxxxx The xxxxxx real xxxxxxxx made xxxx medical xxxxxxxxx based xx falsified xxxx That xx not xxxxxxxx ambition xx is xxxx deceit xxxxxxxxxx in xxxxxxxx must xxxxx compromise xxxxxx Moreover xxx culture xx a xxxxx for xxxxxxxxx behavior xxxxxxx a xxxxxx dangerous xxxxxxxxx Culture xxx become x cause xx behavior xxx it xxxxx excuses xxxxxxxxx anybody's xxxxx the xxx or xxxxxx welfare xxxxxx Unwrapped xxxxxxxx and xxxxxxxxxxxx ReflectionIn xxxx case x am xxxxxxxxxx personally xx consider xxx I xxxxx respond xx a xxxxxxx situation x can xxx I xxxxx do xxx right xxxxx but xxx impact xx family xxxxxxxx legal xxxxxxx or xxxxxx risks xxx compromise xxxx conviction xxxxxxxxxxxx I xxxxx believe xxxxxxxxxx the xxxxx and xxxxx most xxxxxxxxxx would xx the xxxxxxx decision xxxxxx one's xxxx a xxxxxx The xxxxxxxxx shown xx Tyler xxxxxx to xxxx that xx is xxxxx in xxx easy xxxxx that xxxxxxxxx is xxxxxx but xx the xxxxxxx carried xx difficulty x have xxxxx on xxx professional xxxx of xxxxxxxxx the xxxxxxxxxxxxx of xxxxxxxxxxx and xxxxxxxxx inquisitive xxxxxxxxxxxxx In xxxxxxxxxx positions x would xxxxxxx ethics xxxxxxxx inculcate xxxxxxxxx reporting xxxxxxxxxx and xxxxxx ethical xxxxxxxx along xxxx performance xxxxxxx set xxx tone xxxx organizations xxxxxxx integrity xxxxxx ethically xxxxxxx fear xxxxxxx easier xxx their xxxxxxxxx Creating x culture xx ethical xxxxxxxx will xxxxxxxxxx render xxxxxxxxxxxxxx unnecessary xxx ethical xxxxxxxx will xxxxxxx have xxxxxx the xxxx not xxx exception xxxxxxxxxxxxxxxxxxxx had x been xx Tyler xxxxxxxx shoes x would xxxx still xxxxx to xx through xxx regulators xxxxxxx frameworks xx proposed xx Rest xxx stakeholder xxxxxx promote xxxxxxxxxxxxxx where xxxxxx safety xxx trust xxx undermined xxx startup xxxxxxx of xxxxxxx Valley xxxxxxxx risk xxx innovation xxx risk-taking xxxxxx not xxxxx malpractice xxxxxxxxxx in xxx health xxxxxx The xxxxxxxx story xx one xxxx describes xxx a xxxxxxx of x startup xxx the xxxxxxxxxx of xxxxxxxxx behavior xxx leaders xxxxxxxxx and xxxxxxxxxxxx must xxxxxxxxxx that xxxxxx ambition xx an xxxxxxxxx virtue xx never xxxxx before xxxxxxxxxx ReferencesCarroll x B xxxxx J x Business xxxxxxx Ethics xxxxxxxxxxxxxx stakeholder xxxxxxxxxx th xx Cengage xxxxxxxx Ethics xxxxxxxxx Theranos xxx Blood xxxxxxxxxx of xxxxx at xxxxxx https xxxxxxxxxxxxxxx utexas xxx wp-content xxxxxxx Theranos-Bad-Blood xxxxxxxx Clara xxxxxxxxxx n x Teaching xxxx Interview xx Theranos xxxxxxxxxxxxx Tyler xxxxxx - xxxxxxxx Center xxx Applied xxxxxx https xxx scu xxx ethics xxxxxxxxxxx business-ethics xxxxxxxxx teaching-note-interview-of-theranos-whistleblower-tyler-shultzMore Articles From MTG 345 Context of Business
.ico)
.ico)
.ico)
